While these preclinical studies show evident potential of uPAR as target for atherosclerosis targeting, the concept has not yet been progressed toward a clinical application neither for therapy nor for diagnostic monitoring via molecular targeted imaging. This evidence concerns the gene PLAUR and atherosclerosis.